Scarica l'app Stockscreener
1.21
0.82%
-0.01
Dopo l'orario di chiusura:
1.24
0.03
+2.48%
Precedente Chiudi:
$1.22
Aprire:
$1.23
Volume 24 ore:
20,680
Relative Volume:
0.49
Capitalizzazione di mercato:
$4.03M
Reddito:
-
Utile/perdita netta:
$-11.91M
Rapporto P/E:
-0.1365
EPS:
-8.8661
Flusso di cassa netto:
$-10.83M
1 W Prestazione:
-7.63%
1M Prestazione:
-30.06%
6M Prestazione:
-67.90%
1 anno Prestazione:
-91.87%
Intervallo 1D:
$1.18
$1.2599
Intervallo di 1 settimana:
$1.1217
$1.3419
Portata 52W:
$1.07
$22.36
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Nome
Silexion Therapeutics Corp
Settore
Industria
Telefono
972-8-6286005
Indirizzo
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
1.21 | 4.03M | 0 | -11.91M | -10.83M | -8.8661 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Silexion Therapeutics Corp Borsa (SLXN) Ultime notizie
EBIT per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
Hedge Fund Bets: Will Silexion Therapeutics Corp Equity Warrant benefit from government policy2026 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Market Recap: Whats the profit margin of Silexion Therapeutics Corp2026 Historical Comparison & Technical Entry and Exit Alerts - baoquankhu1.vn
Shorts Report: Whats the beta of Silexion Therapeutics Corp Equity Warrant stock2026 Growth vs Value & Real-Time Buy Signal Notifications - baoquankhu1.vn
Top Silexion Executive Quietly Unloads a Chunk of Company Stock - TipRanks
Silexion Therapeutics (SLXN) CSO logs sale-to-cover share transaction - Stock Titan
Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors - MSN
Silexion Therapeutics (SLXN) price target decreased by 33.33% to 6.12 - MSN
Silexion Therapeutics Receives Israeli Ministry of Health Approval for Phase 2/3 Trial of SIL204 in Locally Advanced Pancreatic Cancer - geneonline.com
Investor Mood: Can Silexion Therapeutics Corp be recession proofWeekly Trade Summary & Weekly High Return Opportunities - baoquankhu1.vn
Silexion Therapeutics Announces Immediate Board Membership Change - tipranks.com
Ilan Levin removed from Silexion Therapeutics board - TradingView
Board at Silexion Therapeutics (NASDAQ: SLXN) removes Ilan Levin - Stock Titan
Is Silexion Therapeutics Corp a strong growth stockMarket Weekly Review & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204 - TipRanks
Silexion Shareholders Reject Capital Increase and Plan Amendments - The Globe and Mail
Silexion Therapeutics Receives Israeli Ministry of Health Approval for Phase 2/3 Clinical Trial of SIL204 in Advanced Pancreatic Cancer - minichart.com.sg
Silexion gets Israeli approval for pancreatic cancer trial - Investing.com
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewswire
Silexion gains approval for SIL204 pancreatic cancer trial - TipRanks
Silexion Granted Approval to Launch Human Trials That Could Redefine the Future of Cancer Treatment - Benzinga
Regulators clear Silexion (NASDAQ: SLXN) to begin SIL204 pancreatic cancer trial - Stock Titan
Silexion receives Israeli approval for pancreatic cancer trial - Investing.com
Silexion Therapeutics Corp Receives Approval to Initiate Phase 2/3 Clinical Trial Of SIL204 in Locally Advanced Pancreatic Cancer - MarketScreener
Silexion Therapeutics Corp 8-K Filing – Share Capital Increase Proposal Not Approved (March 2026) - Minichart
Silexion Therapeutics Corp announced plans to submit its Phase 2/3 clinical trial application to German regulators by the end of this quarter. - bitget.com
Silexion Therapeutics shareholders reject share capital and equity plan increases By Investing.com - Investing.com South Africa
Silexion Therapeutics shareholders reject share capital and equity plan increases - Investing.com India
Shareholders at Silexion (SLXN) vote down capital and evergreen increase proposals - Stock Titan
Growth Report: Can Silexion Therapeutics Corp Equity Warrant reach resistance levels soon2026 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - baoquankhu1.vn
EPS Watch: Can Silexion Therapeutics Corp Equity Warrant expand its profit margins2026 Snapshot & Fast Moving Trade Plans - baoquankhu1.vn
Form 8K Silexion Therapeutics Corp For: 3 February - Investing.com
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Buy Rating, Maintains Target Price $6 - 富途牛牛
Tangible book value per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
SLXNW Financials: Income Statement, Balance Sheet & Cash Flow | Silexion Therapeutics Corp - Stock Titan
Silexion Therapeutics Corp: Clinical-Stage KRAS Oncology Innovations and siRNA Pipeline for Pancreatic Cancer - Minichart
Silexion Therapeutics Reports 2025 Financial Results and Clinical Program Updates - geneonline.com
Biotech Silexion lines up 2026 pancreatic cancer trial after $18.6M cash raise - Stock Titan
Silexion Therapeutics 10-K: $11.9M net loss, cash $6.08M; operating loss $11.63M - TradingView
Silexion Therapeutics (NASDAQ: SLXN) outlines SIL204 KRAS cancer strategy in 10-K - Stock Titan
Silexion Therapeutics Corp Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Growth Recap: Is Silexion Therapeutics Corp Equity Warrant a potential multi baggerTrade Volume Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
Setup Watch: Can Silexion Therapeutics Corp Equity Warrant stock outperform in a bear marketBreakout Watch & Entry Point Confirmation Signals - baoquankhu1.vn
Silexion Therapeutics Corp Auditor Raises 'Going Concern' Doubt - MarketScreener
SLXN SEC FilingsSilexion Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: MetaVia (MTVA), Immunome (IMNM) - The Globe and Mail
Fed Meeting: Can Silexion Therapeutics Corp Equity Warrant reach resistance levels soonQuarterly Profit Summary & Fast Gain Stock Trading Tips - baoquankhu1.vn
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting - Bitget
Rally Mode: Is Silexion Therapeutics Corp a defensive stock2025 Price Targets & Entry and Exit Point Strategies - baoquankhu1.vn
SLXN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Book value per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
Silexion Therapeutics Corp Azioni (SLXN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):